Stock Events

Stock Events

Edgewise Therapeutics 

$33.33
13
+$0.19+0.57% Thursday 19:58

Statistics

Day High
33.52
Day Low
32.26
52W High
33.52
52W Low
10.6
Volume
971,022
Avg. Volume
975,019
Mkt Cap
3.58B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.49
-0.44
-0.39
-0.34
Expected EPS
-0.486183
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-335.59MNet Income

Analyst Ratings

$43.00Average Price Target
The highest estimate is 50.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EWTX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, directly competing in the muscular dystrophy market where Edgewise Therapeutics is also active.
Dyadic International DE
DYAI
Mkt Cap40.89M
Dyadic International, Inc. works on developing and commercializing protein-based therapeutics for diseases, including muscular disorders, which puts them in direct competition with Edgewise Therapeutics' focus.
Silence Therapeutics
SLN
Mkt Cap338.2M
Silence Therapeutics develops gene silencing and RNA interference (RNAi) therapeutics, targeting conditions that overlap with Edgewise Therapeutics' focus areas, including muscular diseases.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics is involved in the discovery and commercialization of orally administered small molecule drugs and gene therapies for muscular dystrophies, competing in the same therapeutic areas as Edgewise Therapeutics.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, gene editing, and gene regulation, targeting diseases that overlap with Edgewise Therapeutics' focus, such as muscular dystrophies.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including therapies for muscular dystrophies, directly competing with Edgewise Therapeutics.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is focused on developing gene-based medicines for serious diseases, including muscular dystrophies, which could compete with Edgewise Therapeutics' gene-targeted therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in developing and commercializing therapies for treating cystic fibrosis and other serious diseases, including a focus on gene editing and therapy that could extend to muscular diseases, indirectly competing with Edgewise Therapeutics.

About

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Show more...
CEO
Dr. Kevin Koch Ph.D.
Employees
117
Country
US
ISIN
US28036F1057

Listings

BOATS
BOATS
EWTX.BOATS
XNAS
US
EWTX

0 Comments

Share your thoughts

FAQ

What is Edgewise Therapeutics stock price today?▼
The current price of EWTX is $33.33 USD — it has increased by +0.57% in the past 24 hours. Watch Edgewise Therapeutics stock price performance more closely on the chart.
What is Edgewise Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Edgewise Therapeutics stocks are traded under the ticker EWTX.
Is Edgewise Therapeutics stock price growing?▼
EWTX stock has risen by +8.07% compared to the previous week, the month change is a +15.69% rise, over the last year Edgewise Therapeutics has showed a +145.43% increase.
What is Edgewise Therapeutics market cap?▼
Today Edgewise Therapeutics has the market capitalization of 3.58B
When is the next Edgewise Therapeutics earnings date?▼
Edgewise Therapeutics is going to release the next earnings report on May 07, 2026.
What were Edgewise Therapeutics earnings last quarter?▼
EWTX earnings for the last quarter are -0.47 USD per share, whereas the estimation was -0.44 USD resulting in a -7.78% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Edgewise Therapeutics revenue for the last year?▼
Edgewise Therapeutics revenue for the last year amounts to 0 USD.
What is Edgewise Therapeutics net income for the last year?▼
EWTX net income for the last year is -335.59M USD.
How many employees does Edgewise Therapeutics have?▼
As of April 03, 2026, the company has 117 employees.
In which sector is Edgewise Therapeutics located?▼
Edgewise Therapeutics operates in the Health Care sector.
When did Edgewise Therapeutics complete a stock split?▼
Edgewise Therapeutics has not had any recent stock splits.
Where is Edgewise Therapeutics headquartered?▼
Edgewise Therapeutics is headquartered in Boulder, US.